Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
63°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Replicel Life Sciences Inc
(OP:
REPCF
)
N/A
UNCHANGED
Last Price
Updated: 11:20 AM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Replicel Life Sciences Inc
RepliCel Provides Corporate Update
November 28, 2022
Via
ACCESSWIRE
RepliCel Announces Material Patent Milestones in Key Markets
August 04, 2022
Via
ACCESSWIRE
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections
August 02, 2022
Via
ACCESSWIRE
RepliCel’s Manufacturing Inspected by Japan’s PMDA
July 28, 2022
After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel’s Manufacturing Inspected by Japan’s PMDA
July 28, 2022
Via
ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
July 26, 2022
Via
ACCESSWIRE
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
July 26, 2022
This press release replaces the press release disseminated July 26, 2022 at 06:00 EDT. The press release contained the wrong image - one intended for a future press release. The corrected press release...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
July 26, 2022
Via
ACCESSWIRE
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
July 26, 2022
Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces Material Patent Milestones
January 10, 2022
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key markets VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / RepliCel Life Sciences Inc....
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
RepliCel Closed Final Tranche of Strategic Investment Commitment
December 21, 2021
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Terminates License Agreement with Shiseido
December 21, 2021
VANCOUVER, BC / ACCESSWIRE / December 21, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FSE:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
November 11, 2021
Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection parameters using donated human tissue VANCOUVER, BC / ACCESSWIRE / November 11,...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
November 09, 2021
RepliCel's CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearance VANCOUVER, BC / ACCESSWIRE / November 9, 2021 / RepliCel Life Sciences Inc....
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
October 28, 2021
Trademark registrations kickoff pre-commercial planning VANCOUVER, BC / ACCESSWIRE / October 28, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces Dermal Injector Update
October 27, 2021
Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality compliance, and commercial-scale production capabilities VANCOUVER, BC / ACCESSWIRE /...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
October 18, 2021
After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking Shiseido's full compliance with the agreement or return of the license and all collaboration...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
October 12, 2021
Kunihiko Suzuki, one of the leading pioneers in Japan's emerging regenerative medicine industry, commits to a role as Senior Strategic Advisor to RepliCel's Board of Directors VANCOUVER, BC /...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Economy
Exposures
Economy
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
September 16, 2021
- Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
July 07, 2021
Clinical development of RepliCel's skin rejuvenation and tendon regeneration injectables continues to meet milestones on path to commercialization in Japan VANCOUVER, BC / ACCESSWIRE / July 7, 2021 /...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Adds Independent Director
June 15, 2021
Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC / ACCESSWIRE / June 15, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2),...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
RepliCel Launches Testing of Dermal Injector Units
May 25, 2021
Initial units delivered and first phase of functional testing nearly complete VANCOUVER, BC / ACCESSWIRE / May 25, 2021 / RepliCel Life Sciences Inc. (TSX.V:RP) (OTCPK:REPCF) (FRA:P6P2) ("RepliCel" or...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
May 19, 2021
Clinical Research Organization, Accerise Inc., Has Been Retained To Work With RepliCel and Its Other Service Providers To Prepare Study Documentation, Plans, and Approvals for Clinical Evaluation by...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
May 17, 2021
Professor Akimichi Morita, Vice Director of Nagoya City University Hospital, will lead RepliCel's Skin Rejuvenation Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 17, 2021 / RepliCel Life...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
May 11, 2021
Early identification of unique cell markers is expected to have valuable impact on patents, clinical efficacy, and manufacturing optimization VANCOUVER, BC / ACCESSWIRE / May 11, 2021 / RepliCel Life...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
RepliCel Announces Record Year in Patents Granted
May 05, 2021
Patents Granted in the United States, China, South Korea, Japan, Israel and New Zealand for Dermal Injector and Tendon Regeneration Technologies VANCOUVER, BC / ACCESSWIRE / May 5, 2021 / RepliCel Life...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
May 03, 2021
Professor Tsukasa Kumai, member of the Japan's Olympic Committee Medical and Scientific Staff, will lead RepliCel's Tendon Regeneration Clinical Testing in Japan VANCOUVER, BC / ACCESSWIRE / May 3,...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
RepliCel Closes Second Tranche of Strategic Investment Commitment
April 29, 2021
MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment Agreement VANCOUVER, BC / ACCESSWIRE / April 29, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF) (TSXV:RP)...
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.